Online Articles: Case ReportsCrizotinib Response in a Late Relapse of ALK-positive Lung AdenocarcinomaZito Marino, Federica MSc*; Morabito, Alessandro MD†; Gridelli, Cesare MD‡; Rocco, Gaetano MD§; Liguori, Giuseppina MSc*; De Rosa, Nicla MD∥; Botti, Gerardo MD*; Franco, Renato PhD*,¶ Author Information *Pathology Unit †Medical Oncology Unit, Department of Thoracic Surgical and Medical Oncology §Department of Thoracic Surgical and Medical Oncology, Division of Thoracic Surgery, Istituto Nazionale dei Tumori “Fondazione G. Pascale”-IRCCS ∥Department of Oncology and Anatomic Pathology, Hospital of National Relevance (AORN) Vincenzo Monaldi ¶Pathology Unit, Department of Psychiatry, University of Naples SUN, Naples ‡Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy Informed consent was obtained from the patient included in the study. The authors declare no conflict of interest. Reprints: Renato Franco, PhD, Pathology Unit, Istituto Nazionale dei Tumori “Fondazione G. Pascale,” Via Mariano Semmola, Naples 80131, Italy (e-mails: [email protected]; [email protected]). Applied Immunohistochemistry & Molecular Morphology: October 2016 - Volume 24 - Issue 9 - p e86-e88 doi: 10.1097/PAI.0000000000000328 Buy Metrics Abstract Anaplastic lymphoma kinase (ALK) rearrangement is a therapeutic target in non–small cell lung cancer. To date, few reports have been provided related to ALK-rearranged late recurrence and sensitivity to the treatment with specific ALK inhibitors. We report a case of a 35-year-old man who underwent a right lower lobe lobectomy for lung adenocarcinoma, and treated with the platinum-based chemotherapy regimen. After 10 healthy years, he developed a lung nodule in the same site as the previous. Cytopathologic diagnosis was lung adenocarcinoma. Furthermore, the pulmonary nodule was considered a late recurrence in relation to the lymph node involvement, the same histotype and the site, ALK fluorescence in situ hybridization test and epidermal growth factor receptor analysis were performed on the formalin-fixed paraffin-embedded specimens of the previous resected tumor, because of inadequacity cytologic sample. Being positive for ALK rearrangement, the patient was treated with crizotinib with a good response. To the best of our knowledge, it is the first case of a late relapse of ALK-positive lung adenocarcinoma sensitive to crizotinib in the literature. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.